Calcium flux-independent NMDA receptor activity is required for Aβ oligomer-induced synaptic loss

Cell Death and Disease

Volumn 6, Issue 6, 2015, Pages

  Birnbaum, J H ^a   Bali, J ^a   Rajendran, L ^a   Nitsch, R M ^a   Tackenberg, C ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM ION; DIZOCILPINE; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; GLUTAMIC ACID; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE P38; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OLIGOMER; PERTUSSIS TOXIN; SYNTHETIC PEPTIDE; 1,2-BIS(2-AMINOPHENOXY)ETHANE-N,N,N',N'-TETRAACETIC ACID; 2-AMINO-5-PHOSPHOPENTANOIC ACID; CALCIUM; DIZOCILPINE MALEATE; EGTAZIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; NEUROPROTECTIVE AGENT; VALINE;

ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DENDRITIC SPINE; ENZYME ACTIVITY; ENZYME INHIBITION; HIPPOCAMPAL SLICE; LONG TERM DEPRESSION; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPTIC LOSS; ALZHEIMER DISEASE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; HIPPOCAMPUS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CALCIUM; DENDRITIC SPINES; DIZOCILPINE MALEATE; EGTAZIC ACID; GLUTAMIC ACID; GTP-BINDING PROTEINS; HIPPOCAMPUS; MEMANTINE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERTUSSIS TOXIN; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; VALINE;

EID: 84989915513     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.160     Document Type: Article

References (43)

1. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572-580.
2. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999; 46: 860-866.
3. Shrestha BR, Vitolo OV, Joshi P, Lordkipanidze T, Shelanski M, Dunaevsky A et al. Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci 2006; 33: 274-282.
4. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27: 2866-2875.
5. Tackenberg C, Brandt R. Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau. J Neurosci 2009; 29: 14439-14450.
6. Tackenberg C, Grinschgl S, Trutzel A, Santuccione AC, Frey MC, Konietzko U et al. NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death Dis 2013; 4: e608.
7. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008; 14: 837-842.
8. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D et al. Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009; 62: 788-801.
9. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M et al. Abeta oligomerinduced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007; 27: 796-807.
10. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST et al. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptordependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007; 282: 11590-11601.
11. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ et al. Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011; 31: 6627-6638.
12. Chung C. NMDA receptor as a newly identified member of the metabotropic glutamate receptor family: clinical implications for neurodegenerative diseases. Mol Cells 2013; 36: 99-104.
13. Nabavi S, Kessels HW, Alfonso S, Aow J, Fox R, Malinow R et al. Metabotropic NMDA receptor function is required for NMDA receptor-dependent long-term depression. Proc Natl Acad Sci USA 2013; 110: 4027-4032.
14. Vissel B, Krupp JJ, Heinemann S F, Westbrook GL. A use-dependent tyrosine dephosphorylation of NMDA receptors is independent of ion flux. Nat Neurosci 2001; 4: 587-596.
15. Nong Y, Huang YQ, Ju W, Kalia LV, Ahmadian G, Wang YT et al. Glycine binding primes NMDA receptor internalization. Nature 2003; 422: 302-307.
16. Barria A, Malinow R. Subunit-specific NMDA receptor trafficking to synapses. Neuron 2002; 35: 345-353.
17. Kessels HW, Nabavi S, Malinow R. Metabotropic NMDA receptor function is required for β -amyloid - induced synaptic depression. Proc Natl Acad Sci USA 2013; 110: 4033-4038.
18. Wesemann W, Sturm G, Fünfgeld EW. Distribution of metabolism of the potential antiparkinson drug memantine in the human. J Neural Transm Suppl 1980; 16: 143-148.
19. Periclou A, Ventura D, Rao N, Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 2006; 79: 134-143.
20. Hoey SE, Williams RJ, Perkinton MS. Synaptic NMDA receptor activation stimulates alphasecretase amyloid precursor protein processing and inhibits amyloid-beta production. J Neurosci 2009; 29: 4442-4460.
21. Xia P, Chen HS, Zhang D, Lipton S A. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci 2010; 30: 11246-11250.
22. Bordji K, Becerril-Ortega J, Buisson A. Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer's disease. Rev Neurosci 2011; 22: 285-294.
23. Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging 2007; 28: 1297-1307.
24. Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci 2010; 30: 11938-11950.
25. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Abeta oligomers. Neurobiol Aging 2008; 29: 1334-1347.
26. Tanabe M, Gähwiler BH, Gerber U. Effects of transient oxygen-glucose deprivation on G-proteins and G-protein-coupled receptors in rat CA3 pyramidal cells in vitro. Europ J Neurosci 1998; 10: 2037-2045.
27. Tamburri A, Dudilot A, Licea S, Bourgeois C, Boehm J. NMDA-receptor activation but not ion flux is required for amyloid-beta induced synaptic depression. Plos One 2013; 8: e65350.
28. Lynch G, Larson J, Kelso S, Barrionuevo G, Schottler F. Intracellular injections of EGTA block induction of hippocampal long-term potentiation. Nature 1983; 305: 719-721.
29. Jensen L E, Bultynck G, Luyten T, Amijee H, Bootman MD, Roderick HL et al. Alzheimer's disease-associated peptide Aβ42 mobilizes ER Ca(2+) via InsP3R-dependent and -independent mechanisms. Front Mol Neurosci 2013; 6: 36.
30. Zhu Y, Pak D, Qin Y, McCormack SG, Kim MJ, Baumgart JP et al. Rap2-JNK removes synaptic AMPA receptors during depotentiation. Neuron 2005; 46: 905-916.
31. Collingridge GL, Peineau S, Howland JG, Wang YT. Long-term depression in the CNS. Nat Rev Neurosci 2010; 11: 459-473.
32. Huang CC, You JL, Wu MY, Hsu KS. Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI.Rab5 complex. Potential role in (S)-3, 5-dihydroxyphenylglycene-induced long term depression. J Biol Chem 2004; 279: 12286-12292.
33. Yang L, Mao L, Tang Q, Samdani S, Liu Z, Wang JQ et al. A novel Ca2+-independent signaling pathway to extracellular signal-regulated protein kinase by coactivation of NMDA receptors and metabotropic glutamate receptor 5 in neurons. J Neurosci 2004; 24: 10846-10857.
34. Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL et al. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 2010; 66: 739-754.
35. Hu N W, Nicoll AJ, Zhang D, Mably AJ, O'Malley T, Purro SA et al. mGlu5 receptors and cellular prion protein mediate amyloid-β-facilitated synaptic long-term depression in vivo. Nat Commun 2014; 5: 3374.
36. Harada J, Sugimoto M. An inhibitor of p38 and JNK MAP kinases prevents activation of caspase and apoptosis of cultured cerebellar granule neurons. Japn J Pharmacol 1999; 79: 369-378.
37. McLaughlin B, Pal S, Tran MP, Parsons AA, Barone FC, Erhardt JA et al. p38 activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidantinduced neuronal apoptosis. J Neurosci 2001; 21: 3303-3311.
38. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006; 5: 160-170.
39. Figueiredo CP, Clarke JR, Ledo JH, Ribeiro FC, Costa CV, Melo HM et al. Memantine rescues transient cognitive impairment caused by high-molecular-weight aβ oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci 2013; 33: 9626-9634.
40. Scheff SW, Price D A, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007; 68: 1507-1508.
41. Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011; 68: 991-998.
42. Stoppini L, Buchs PA, Muller D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 1991; 37: 173-182.
43. Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002; 41: 345-352.